We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$117M
Cap. Flow
+$131M
Cap. Flow %
33.06%
Top 10 Hldgs %
59.9%
Holding
91
New
22
Increased
27
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.78M
2
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$6.98M
3
OCUL icon
Ocular Therapeutix
OCUL
+$5.62M
4
BBIO icon
BridgeBio Pharma
BBIO
+$5.6M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.42M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$6.29M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.74M
3
XLRN
Acceleron Pharma
XLRN
+$2.57M
4
MGNX icon
MacroGenics
MGNX
+$2.15M
5
EPIX
ESSA Pharma
EPIX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 55.88%
2 Financials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
76
Cullinan Oncology
CGEM
$1.09B
– –
-45,000
Closed -$1.16M
CVAC
77
PUT
DELISTED
CureVac
CVAC
– –
-150,000
Closed -$11M
CVRX icon
78
CVRx
CVRX
$127M
– –
-7,500
Closed -$210K
EPIX
79
DELISTED
ESSA Pharma
EPIX
– –
-70,000
Closed -$2M
IONS icon
80
CALL
Ionis Pharmaceuticals
IONS
$8.87B
– –
-75,000
Closed -$2.99M
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
– –
-25,000
Closed -$641K
KALV
82
DELISTED
KalVista Pharmaceuticals
KALV
– –
-50,000
Closed -$1.2M
MGNX icon
83
MacroGenics
MGNX
$278M
– –
-80,000
Closed -$2.15M
MRNA icon
84
CALL
Moderna
MRNA
$24.4B
– –
-12,500
Closed -$2.94M
MRSN
85
DELISTED
Mersana Therapeutics
MRSN
– –
-3,400
Closed -$1.15M
PTGX icon
86
Protagonist Therapeutics
PTGX
$8.89B
– –
-140,100
Closed -$6.29M
QSI icon
87
Quantum-Si Incorporated
QSI
$181M
– –
-75,000
Closed -$920K
CHAQ.U
88
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
– –
-75,000
Closed -$819K
CEREW
89
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-72,466
Closed -$1.04M
1 2 3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Affinity Asset Advisors held 91 positions worth $396M, up 42% from $279M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Affinity Asset Advisors deployed $131M of net new capital in Q3 2021, opening 22 new positions and adding to 27 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 68% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Zentalis Pharmaceuticals, an estimated $3.74M trimmed.

  • Affinity Asset Advisors's largest Q3 2021 buy was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q3 2021, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q3 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $3.74M.
  • Affinity Asset Advisors fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $6.29M.
  • Affinity Asset Advisors's ten largest holdings make up 60% of its $396M portfolio in Q3 2021.
  • Affinity Asset Advisors opened 22 new positions and closed 18 in Q3 2021.
  • Affinity Asset Advisors's portfolio value rose 42% quarter-over-quarter to $396M.

Based on Affinity Asset Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.